Mirdametinib is a medicine used to treat plexiform neurofibromas, which are tumors along nerves in people with neurofibromatosis type 1 (NF1). It is taken by mouth as a capsule, or as a tablet that can be swallowed or mixed into water for people who can't swallow pills. It works by blocking a growth signal that makes these nerve tumors grow.
Every report comes from a Lived member, sent anonymously.
Have you tried Gomekli (Mirdametinib) for Plexiform Neurofibroma?
Mirdametinib, sold under the brand name Gomekli, is a targeted oral medicine for plexiform neurofibromas in people with neurofibromatosis type 1 (NF1). NF1 is a genetic condition that causes noncancerous tumors to grow on nerves. Plexiform neurofibromas are a type of these tumors that grow along nerves and into surrounding tissue, and they can cause pain, visible swelling or changes in appearance, and weakness or trouble with movement, depending on where they are. The FDA has approved Gomekli for adults and children 2 years and older with NF1 whose plexiform neurofibromas are causing symptoms and cannot be completely removed with surgery. A tumor is often considered inoperable because it wraps around or sits close to important structures, grows into nearby tissue or has a rich blood supply, so removing all of it would risk serious harm. A related medicine, selumetinib (Koselugo), is also approved for symptomatic plexiform neurofibromas that cannot be removed, starting at age 1. The two have not been compared directly in a study, so the choice between them is made with an NF1 specialist.
The NF1 gene normally makes a protein called neurofibromin, which works as a brake on cell growth by switching off a growth signal inside cells. In NF1 that brake is missing in certain cells around the nerves, the growth signal stays on, and neurofibromas can form and keep growing. Mirdametinib is a MEK inhibitor, a type of kinase inhibitor. MEK1 and MEK2 are relay proteins further down that same growth-signaling chain. By blocking them, mirdametinib turns down the signal that drives the tumor cells to grow, and in many people the tumor gradually shrinks. It does not correct the underlying genetic change or remove the tumor, which is why treatment usually continues for as long as it helps and side effects are manageable.
Gomekli is taken by mouth twice a day, about 12 hours apart, with or without food, for 21 days, followed by 7 days off. Each 28-day block is one cycle, and cycles repeat. The dose is based on body surface area, a measure calculated from height and weight, so it changes as a child grows. The specialist may lower or pause the dose if side effects become hard to manage. It comes in two forms. Capsules must be swallowed whole and should not be opened, broken or chewed. Tablets for oral suspension can be swallowed whole or, for children and adults who cannot swallow pills, swirled in a small amount of drinking water until they disperse into a cloudy liquid. The liquid should be taken right away and must be thrown out if not taken within 30 minutes. If a dose is missed or vomited, do not take an extra dose; take the next one at the usual time. Before treatment starts, the care team arranges an eye examination and an echocardiogram (an ultrasound of the heart), and a pregnancy test for anyone who could become pregnant.
Rash is the most common side effect, affecting most people who take Gomekli. Teenagers and adults often get an acne-like rash, while younger children more often get other kinds of rash. Dry or itchy skin, hair thinning, and redness, swelling or infection around the fingernails or toenails can also occur. Diarrhea, nausea, vomiting, stomach pain, muscle or joint pain, headache and tiredness are common as well. The care team usually starts skin care at the first sign of a rash, so it is worth reporting early. A rash or other side effect that becomes hard to live with can mean the dose needs to be lowered or paused. Gomekli can affect the eyes, including a blocked vein in the retina (the light-sensing layer at the back of the eye), which can threaten sight. Contact the care team right away about blurred vision, new floaters or flashes of light, loss of vision or side vision, or eye pain or redness. It can also weaken the heart's pumping, measured as the ejection fraction on an echocardiogram. In the main study, this was found on scheduled scans, and in most people it went back to normal. Contact the care team right away about shortness of breath, chest pain, swelling in the legs or feet, or unusual tiredness or weakness. A rash with peeling skin also needs prompt attention.
Gomekli can harm a developing baby. Anyone who could become pregnant should use effective birth control during treatment and for 6 weeks after the last dose, and tell the care team promptly about a known or suspected pregnancy. Men whose partners could become pregnant should use effective birth control during treatment and for 3 months after the last dose. Breastfeeding is not recommended during treatment or for 1 week afterward. Gomekli may also reduce fertility in women; this is worth raising before treatment if future pregnancy matters. No studies have yet tested how Gomekli interacts with other medicines, so the care team and pharmacist should know about every prescription, over-the-counter medicine and supplement. Tell the specialist about any history of heart disease, eye disease such as glaucoma or retinal problems, high blood pressure, or liver or kidney disease. People with these conditions were left out of the main study, so less is known about how the medicine affects them.
Gomekli works slowly. In the main study, tumors that shrank usually took around 8 months to do so, and some took over a year and a half. Progress is checked with MRI scans that measure the tumor's volume. In that study, which had no comparison group, about 4 in 10 adults and about half of children had their tumor shrink by at least 20 percent. No tumor disappeared completely, and in most people who did respond, the shrinkage lasted at least a year. Participants also reported less tumor pain and better quality of life, although these were self-reports without a comparison group. Treatment usually continues as long as the tumor is responding or stable and side effects are tolerable. Regular eye exams, heart scans every 3 months in the first year and then as needed, and skin checks are part of ongoing care. About 1 in 5 adults in the study stopped because of side effects, most often rash. How tumors behave after stopping, and the effects of many years of treatment, are still being studied.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Gomekli (Mirdametinib), what you've noticed, or ask the community a question.